查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1383609

動脈粥狀硬化藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按診斷、治療、給藥途徑、最終用戶、地區和競爭細分

Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Diagnosis, By Treatment, By Route of Administration,By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球動脈粥狀硬化藥物市場價值為 182.7 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為2.43%。動脈粥狀硬化是一種因脂肪堆積而導致動脈狹窄和硬化的疾病存款，仍是全球主要的健康問題。它是心臟病、中風和其他心血管併發症的主要原因，每年導致數百萬人死亡。全球動脈粥狀硬化藥物市場在這種情況日益流行的推動下，近年來出現了顯著成長。

動脈粥狀硬化在世界各地越來越普遍，主要是由於不健康的生活方式，包括不良飲食、缺乏體力活動和吸菸。這創造了龐大的需要治療和管理的患者庫。全球人口老化導致動脈粥狀硬化的風險更高。隨著老年人口的成長，對動脈粥狀硬化藥物的需求也增加。醫療技術和診斷的進步使得能夠及早發現動脈粥狀硬化，促進及時介入和藥物治療。公眾意識活動和教育工作使人們更加意識到自己的心血管健康，從而導致更多的人尋求治療。

全球動脈粥狀硬化藥物市場機會與挑戰並存。隨著動脈粥狀硬化的負擔持續加重，創新和研究對於開發有效的治療方法至關重要。個人化醫療和標靶治療有望改善患者的治療結果。然而，解決與藥物定價、依從性和新興競爭相關的問題對於確保有需要的人能夠獲得動脈粥狀硬化藥物至關重要。最終，製藥公司、醫療保健提供者和政策制定者的合作對於對抗動脈粥狀硬化及其對全球健康的破壞性後果至關重要。

市場概況
預測期 2024-2028
2022 年市場規模 182.7億美元
2028 年市場規模 210.3億美元
2023-2028 年CAGR 2.43%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

主要市場促進因素

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和次要待遇
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球動脈粥狀硬化藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依診斷（踝臂指數、多普勒超音波、超音波心臟檢查、心電圖、血液檢查等）
    • 透過治療（藥物、手術、其他）
    • 依給藥途徑（口服、腸胃外、其他）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類（前 5 名市場參與者的股份）
  • 市場地圖
    • 透過診斷
    • 按治療
    • 依給藥途徑
    • 按最終用戶
    • 按地區

第 6 章：北美動脈粥狀硬化藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過診斷
    • 按治療
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區

第 7 章：歐洲動脈粥狀硬化藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過診斷
    • 按治療
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區

第 8 章：亞太地區動脈粥狀硬化藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過診斷
    • 按治療
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區

第 9 章：南美動脈粥狀硬化藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過診斷
    • 按治療
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區

第 10 章：中東和非洲動脈粥狀硬化藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過診斷
    • 按治療
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 技術發布

第13章：競爭格局

  • F.霍夫曼-拉羅氏有限公司
    • Business Overview
    • Patient Offerings
    • Recent Developments
    • Key Personnel
    • SWOT Analysis
  • 邁蘭公司
  • 梯瓦製藥工業股份有限公司
  • 賽諾菲印度
  • 輝瑞公司
  • 葛蘭素史克公司
  • 諾華公司
  • 默克公司
  • 艾爾建印度私人有限公司
  • 阿斯利康

第 14 章：策略建議

關於我們及免責聲明

簡介目錄
Product Code: 18828

Global Atherosclerosis Drugs Market has valued at USD 18.27 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 2.43% through 2028. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to the accumulation of fatty deposits, remains a major global health concern. It is a leading cause of heart disease, stroke, and other cardiovascular complications, contributing to millions of deaths annually. The Global Atherosclerosis Drugs Market, driven by the increasing prevalence of this condition, has witnessed significant growth in recent years.

Atherosclerosis is increasingly prevalent worldwide, mainly due to unhealthy lifestyles, including poor diet, lack of physical activity, and smoking. This has created a substantial patient pool in need of treatment and management. The aging global population is at a higher risk of atherosclerosis. As the elderly demographic grows, so does the demand for atherosclerosis drugs. Advancements in medical technology and diagnostics have enabled early detection of atherosclerosis, promoting timely intervention and medication. Public awareness campaigns and educational efforts have made people more conscious of their cardiovascular health, leading to more individuals seeking treatment.

The Global Atherosclerosis Drugs Market presents both opportunities and challenges. As the burden of atherosclerosis continues to rise, innovation and research are crucial in developing effective treatments. Personalized medicine and targeted therapies hold promise in improving patient outcomes. However, addressing issues related to drug pricing, adherence, and emerging competition will be essential to ensure that atherosclerosis drugs remain accessible to those in need. Ultimately, the collaboration of pharmaceutical companies, healthcare providers, and policymakers is essential in the fight against atherosclerosis and its devastating consequences on global health.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 18.27 Billion
Market Size 2028USD 21.03 Billion
CAGR 2023-20282.43%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Atherosclerosis is Driving the Global Atherosclerosis Drugs Market

Atherosclerosis, a condition characterized by the build-up of plaque in arteries, is becoming increasingly prevalent worldwide. This arterial disease poses significant health risks, including heart attacks and strokes, making it a global healthcare concern. Consequently, the global atherosclerosis drugs market is on the rise, driven by the growing need for effective treatments. Modern lifestyles often involve long hours of sitting, reduced physical activity, and poor dietary choices. These factors contribute to obesity, hypertension, and elevated cholesterol levels, all of which increase the risk of atherosclerosis.

Diets high in saturated fats, trans fats, and processed foods are common in many parts of the world. These diets not only contribute to obesity but also raise the levels of LDL (low-density lipoprotein) cholesterol, a major risk factor for atherosclerosis. Atherosclerosis is more prevalent among older individuals. As the global population ages, the incidence of atherosclerosis is expected to increase, placing additional strain on healthcare systems. Tobacco use remains a significant risk factor for atherosclerosis. Despite public health campaigns to reduce smoking rates, many individuals continue to smoke, further exacerbating the problem. Diabetes is associated with a higher risk of atherosclerosis due to elevated blood sugar levels and other metabolic changes. The rising prevalence of diabetes worldwide contributes to the increasing incidence of atherosclerosis.

The rising prevalence of atherosclerosis has led to a growing demand for effective treatments, which, in turn, is driving the global atherosclerosis drugs market. Several factors are contributing to the market's expansion. Pharmaceutical companies are investing heavily in research and development to create innovative drugs for atherosclerosis treatment. These efforts aim to develop more effective medications with fewer side effects. Public awareness campaigns and educational initiatives are helping individuals recognize the risk factors and symptoms of atherosclerosis, leading to earlier diagnosis and treatment. Lifestyle modifications, including diet and exercise, play a crucial role in managing atherosclerosis. This has spurred the development of complementary products and services, such as dietary supplements and fitness programs, which are also contributing to the market's growth. Technological advancements in diagnostic imaging techniques, such as CT scans and angiography, allow for earlier and more accurate detection of atherosclerosis, facilitating timely intervention and treatment. Collaboration between pharmaceutical companies, healthcare providers, and research institutions is fostering innovation and the development of comprehensive treatment approaches.

Increasing Geriatric Population is Driving the Global Atherosclerosis Drugs Market

The global healthcare landscape is witnessing a significant transformation as the world's population ages. One of the key health concerns associated with aging is atherosclerosis, a condition characterized by the buildup of plaque in the arteries, leading to various cardiovascular diseases. As the aging population continues to grow, the demand for atherosclerosis drugs is on the rise, propelling the global atherosclerosis drugs market to new heights. The global population is aging at an unprecedented rate. According to the World Health Organization (WHO), the proportion of people aged 60 and over is expected to double by 2050, accounting for 22% of the world's population. As individuals age, their risk of developing atherosclerosis and related cardiovascular conditions significantly increases. This demographic shift is a primary driver behind the growing demand for atherosclerosis drugs.

With atherosclerosis as a key contributor to heart attacks, strokes, and other cardiovascular diseases, the rising aging population directly correlates with an increased incidence of these conditions. This necessitates a greater need for effective atherosclerosis drugs. Advances in healthcare, nutrition, and lifestyle have contributed to longer life expectancy. While this is undoubtedly a positive development, it also means that individuals are exposed to the risk of atherosclerosis and its complications for a more extended period, further fueling the demand for treatment options. Aging is associated with various risk factors for atherosclerosis, such as hypertension, diabetes, and high cholesterol levels. As the population ages, the prevalence of these risk factors rises, underscoring the need for pharmacological interventions.

Pharmaceutical companies are exploring novel therapeutic approaches to manage atherosclerosis. These include targeted therapies that aim to reduce plaque buildup and inflammation within arterial walls. Advancements in genomics and personalized medicine are enabling healthcare providers to tailor atherosclerosis treatments to individual patients, optimizing efficacy and minimizing side effects. Researchers are investigating combinations of drugs with complementary mechanisms of action to enhance treatment outcomes and reduce the risk of disease progression. Pharmaceutical companies are also investing in educational initiatives to raise awareness about atherosclerosis risk factors and prevention strategies, emphasizing the importance of a healthy lifestyle.

Key Market Challenges

Regulatory Barriers

One of the most significant hurdles for the atherosclerosis drugs market is the stringent regulatory framework governing the approval of new drugs. Regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require extensive clinical trials to demonstrate both the safety and efficacy of new drugs. This process is not only time-consuming but also costly. Moreover, the bar for proving effectiveness is continually raised, making it more challenging for pharmaceutical companies to bring new therapies to market.

Increasing Competition

The atherosclerosis drugs market is fiercely competitive, with numerous pharmaceutical companies vying for market share. Established players, such as Pfizer and AstraZeneca, dominate the market with well-established drugs like Lipitor and Crestor. Entering this market and gaining a foothold can be challenging for newer, smaller companies, particularly when dealing with the complex regulatory landscape and the need for significant financial resources.

Intellectual Property Concerns

Pharmaceutical companies invest heavily in research and development to create innovative atherosclerosis drugs. Protecting their intellectual property through patents is crucial, as it provides exclusivity for a certain period, allowing them to recoup their investments. However, once patents expire, generic versions of the drugs become available, leading to reduced revenues for the original manufacturers. Navigating the complex landscape of patents, generic competition, and exclusivity rights poses an ongoing challenge for companies in this market.

Evolving Treatment Paradigms

Advancements in medical research and technology have led to evolving treatment paradigms in atherosclerosis management. Lifestyle modifications, such as dietary changes and increased physical activity, are often recommended as initial interventions. This shift toward prevention and early intervention can potentially reduce the need for drug therapies, impacting the growth of the atherosclerosis drugs market.

Price Pressures and Healthcare Costs

Atherosclerosis drugs, especially newer and more advanced therapies, can be expensive. As healthcare costs continue to rise globally, payers, including government healthcare systems and private insurers, are putting pressure on drug manufacturers to lower prices. This creates a challenge for pharmaceutical companies to balance the need for profitability with the demand for more affordable medications.

Patient Adherence

Atherosclerosis drugs are often prescribed for long periods, sometimes even for life. Patient adherence to medication regimens is crucial for achieving positive treatment outcomes. However, ensuring that patients consistently take their prescribed medications can be challenging. Factors such as forgetfulness, cost, and concerns about side effects can all contribute to poor adherence rates.

Key Market Trends

Technological Advancements

Atherosclerosis, a chronic condition characterized by the buildup of plaque in arteries, has long been a significant health concern worldwide. It is a leading cause of heart disease, strokes, and other cardiovascular diseases, contributing to millions of deaths annually. However, with the relentless march of technological advancements in the healthcare sector, there is newfound hope for combating atherosclerosis. These innovations are revolutionizing the development, diagnosis, and treatment of atherosclerosis, which in turn is driving the growth of the global atherosclerosis drugs market.

Modern imaging technologies like CT angiography, magnetic resonance imaging (MRI), and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, allowing healthcare professionals to visualize plaque buildup and assess its severity accurately. Blood tests now incorporate biomarkers that can detect specific molecules associated with atherosclerosis, such as high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2). These tests aid in early detection and risk assessment. AI and machine learning algorithms are being employed to analyze medical imaging and patient data, helping to identify patterns and predict atherosclerosis development. This technology enhances the efficiency and accuracy of diagnosis.

Advances in pharmacogenomics and personalized medicine are enabling the development of drugs that target specific genetic markers associated with atherosclerosis, improving treatment efficacy and minimizing side effects. Nanoparticles are being utilized to deliver drugs directly to arterial plaques, enhancing drug effectiveness while minimizing systemic side effects. Technological innovations have led to the development of drug-eluting stents, which are coated with medications that prevent restenosis (re-narrowing of arteries) after angioplasty and stent placement. Cutting-edge gene-editing techniques like CRISPR-Cas9 hold the potential to address the genetic factors contributing to atherosclerosis, opening up new avenues for treatment development.

Telehealth platforms and wearable devices enable healthcare providers to remotely monitor patients with atherosclerosis, allowing for early intervention and reducing hospitalization rates. Mobile applications and wearable devices can track vital signs, physical activity, and dietary habits, empowering patients to take a proactive role in managing their condition. The analysis of large datasets is providing valuable insights into atherosclerosis epidemiology, treatment outcomes, and patient responses, helping refine treatment approaches.

Segmental Insights

Route of Administration Insights

Based on the category of Route of Administration, Oral emerged as the dominant player in the global market for Atherosclerosis Drugs in 2022. The oral route of administration, where medications are taken by mouth in the form of tablets, capsules, or liquids, has emerged as the preferred choice for atherosclerosis drugs for several compelling reasons. One of the primary advantages of the oral route is its simplicity and ease of use. Patients can take medications at home without the need for medical supervision or invasive procedures. This convenience often leads to better adherence to treatment regimens, improving overall patient outcomes. Patients are generally more receptive to oral medications because they are familiar with this method. This ease of acceptance can lead to increased patient compliance, a critical factor in managing chronic conditions like atherosclerosis. Oral medications can be formulated in various ways, including extended-release formulations that provide continuous drug delivery over time. This allows for tailored treatment plans to meet individual patient needs. Oral medications tend to be more cost-effective than other routes of administration, such as intravenous or transdermal options. This affordability can make treatment more accessible to a broader range of patients. Pharmaceutical companies often focus their research and development efforts on oral formulations due to their wide market appeal. This results in a more extensive selection of oral atherosclerosis drugs and innovative formulations. The oral route typically presents fewer side effects compared to other administration methods, such as injections. This can enhance the overall patient experience and treatment compliance.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are at the forefront of diagnosing and treating atherosclerosis. They serve as the primary points of contact for patients experiencing cardiovascular symptoms and are essential in managing this condition effectively. Hospitals and clinics play a critical role in diagnosing atherosclerosis through various methods, including imaging techniques like angiography, ultrasound, and CT scans. Early detection is vital for initiating appropriate treatment. Once diagnosed, patients often require medical intervention to manage their atherosclerosis. Hospitals provide a wide range of treatment options, including medication and surgical procedures such as angioplasty or coronary artery bypass grafting (CABG). After surgical procedures or severe cardiac events, hospitals offer rehabilitation programs to help patients recover and prevent the progression of atherosclerosis. These programs include lifestyle modifications, exercise regimens, and dietary counseling. Hospitals and clinics are also crucial in dispensing atherosclerosis drugs to patients. Statins, antiplatelet medications, and antihypertensive drugs are commonly prescribed to manage atherosclerosis and reduce the risk of complications.

Regional Insights

North America emerged as the dominant player in the global Atherosclerosis Drugs market in 2022, holding the largest market share in terms of value. One of the primary reasons behind North America's dominance in the global atherosclerosis drugs market is the high incidence of atherosclerosis in the region. Factors such as a sedentary lifestyle, unhealthy dietary habits, and a growing aging population have contributed to a significant prevalence of atherosclerotic diseases, including coronary artery disease and peripheral artery disease. This high disease burden has led to a substantial demand for atherosclerosis drugs. North America boasts a well-developed and advanced healthcare infrastructure. The region is home to some of the world's leading pharmaceutical companies, research institutions, and healthcare providers. This infrastructure enables the efficient development, testing, and distribution of atherosclerosis drugs, fostering innovation and driving market growth. North America invests heavily in research and development (R&D) activities related to atherosclerosis drugs. Pharmaceutical companies in the United States and Canada dedicate substantial resources to discover and develop novel therapies for atherosclerosis. These investments not only drive product innovation but also enhance the competitiveness of the North American market in the global arena.

Key Market Players

F. Hoffmann-La Roche Ltd.

Mylan N.V.

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

Pfizer Inc.

GlaxoSmithKline plc

Novartis AG

Merck & Co

Allergan Plc

AstraZeneca

Report Scope:

In this report, the Global Atherosclerosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atherosclerosis Drugs Market, By Diagnosis:

  • Ankle-brachial Index
  • Doppler Ultrasound
  • Echocardiogram Electrocardiogram Blood Tests
  • Others

Atherosclerosis Drugs Market, By Treatment :

  • Medication
  • Surgery
  • Others

Atherosclerosis Drugs Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Atherosclerosis Drugs Market, By End user:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Atherosclerosis Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Atherosclerosis Drugs Market.

Available Customizations:

  • Global Atherosclerosis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Treatment
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atherosclerosis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
    • 5.2.2. By Treatment (Medication, Surgery, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Diagnosis
    • 5.3.2. By Treatment
    • 5.3.3. By Route of Administration
    • 5.3.4. By End User
    • 5.3.5. By Region

6. North America Atherosclerosis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnosis
    • 6.2.2. By Treatment
    • 6.2.3. By Route of Administration
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. United States Atherosclerosis Drugs Market Outlook
        • 6.2.5.1.1. Market Size & Forecast
        • 6.2.5.1.1.1. By Value
        • 6.2.5.1.2. Market Share & Forecast
        • 6.2.5.1.2.1. By Diagnosis
        • 6.2.5.1.2.2. By Treatment
        • 6.2.5.1.2.3. By Route of Administration
        • 6.2.5.1.2.4. By End User
      • 6.2.5.2. Canada Atherosclerosis Drugs Market Outlook
        • 6.2.5.2.1. Market Size & Forecast
        • 6.2.5.2.1.1. By Value
        • 6.2.5.2.2. Market Share & Forecast
        • 6.2.5.2.2.1. By Diagnosis
        • 6.2.5.2.2.2. By Treatment
        • 6.2.5.2.2.3. By Route of Administration
        • 6.2.5.2.2.4. By End User
      • 6.2.5.3. Mexico Atherosclerosis Drugs Market Outlook
        • 6.2.5.3.1. Market Size & Forecast
        • 6.2.5.3.1.1. By Value
        • 6.2.5.3.2. Market Share & Forecast
        • 6.2.5.3.2.1. By Diagnosis
        • 6.2.5.3.2.2. By Treatment
        • 6.2.5.3.2.3. By Route of Administration
        • 6.2.5.3.2.4. By End User

7. Europe Atherosclerosis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnosis
    • 7.2.2. By Treatment
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. France Atherosclerosis Drugs Market Outlook
        • 7.2.5.1.1. Market Size & Forecast
        • 7.2.5.1.1.1. By Value
        • 7.2.5.1.2. Market Share & Forecast
        • 7.2.5.1.2.1. By Diagnosis
        • 7.2.5.1.2.2. By Treatment
        • 7.2.5.1.2.3. By Route of Administration
        • 7.2.5.1.2.4. By End User
      • 7.2.5.2. Germany Atherosclerosis Drugs Market Outlook
        • 7.2.5.2.1. Market Size & Forecast
        • 7.2.5.2.1.1. By Value
        • 7.2.5.2.2. Market Share & Forecast
        • 7.2.5.2.2.1. By Diagnosis
        • 7.2.5.2.2.2. By Treatment
        • 7.2.5.2.2.3. By Route of Administration
        • 7.2.5.2.2.4. By End User
      • 7.2.5.3. United Kingdom Atherosclerosis Drugs Market Outlook
        • 7.2.5.3.1. Market Size & Forecast
        • 7.2.5.3.1.1. By Value
        • 7.2.5.3.2. Market Share & Forecast
        • 7.2.5.3.2.1. By Diagnosis
        • 7.2.5.3.2.2. By Treatment
        • 7.2.5.3.2.3. By Route of Administration
        • 7.2.5.3.2.4. By End User
      • 7.2.5.4. Italy Atherosclerosis Drugs Market Outlook
        • 7.2.5.4.1. Market Size & Forecast
        • 7.2.5.4.1.1. By Value
        • 7.2.5.4.2. Market Share & Forecast
        • 7.2.5.4.2.1. By Diagnosis
        • 7.2.5.4.2.2. By Treatment
        • 7.2.5.4.2.3. By Route of Administration
        • 7.2.5.4.2.4. By End User
      • 7.2.5.5. Spain Atherosclerosis Drugs Market Outlook
        • 7.2.5.5.1. Market Size & Forecast
        • 7.2.5.5.1.1. By Value
        • 7.2.5.5.2. Market Share & Forecast
        • 7.2.5.5.2.1. By Diagnosis
        • 7.2.5.5.2.2. By Treatment
        • 7.2.5.5.2.3. By Route of Administration
        • 7.2.5.5.2.4. By End User

8. Asia Pacific Atherosclerosis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnosis
    • 8.2.2. By Treatment
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. China Atherosclerosis Drugs Market Outlook
        • 8.2.5.1.1. Market Size & Forecast
        • 8.2.5.1.1.1. By Value
        • 8.2.5.1.2. Market Share & Forecast
        • 8.2.5.1.2.1. By Diagnosis
        • 8.2.5.1.2.2. By Treatment
        • 8.2.5.1.2.3. By Route of Administration
        • 8.2.5.1.2.4. By End User
      • 8.2.5.2. India Atherosclerosis Drugs Market Outlook
        • 8.2.5.2.1. Market Size & Forecast
        • 8.2.5.2.1.1. By Value
        • 8.2.5.2.2. Market Share & Forecast
        • 8.2.5.2.2.1. By Diagnosis
        • 8.2.5.2.2.2. By Treatment
        • 8.2.5.2.2.3. By Route of Administration
        • 8.2.5.2.2.4. By End User
      • 8.2.5.3. South Korea Atherosclerosis Drugs Market Outlook
        • 8.2.5.3.1. Market Size & Forecast
        • 8.2.5.3.1.1. By Value
        • 8.2.5.3.2. Market Share & Forecast
        • 8.2.5.3.2.1. By Diagnosis
        • 8.2.5.3.2.2. By Treatment
        • 8.2.5.3.2.3. By Route of Administration
        • 8.2.5.3.2.4. By End User
      • 8.2.5.4. Japan Atherosclerosis Drugs Market Outlook
        • 8.2.5.4.1. Market Size & Forecast
        • 8.2.5.4.1.1. By Value
        • 8.2.5.4.2. Market Share & Forecast
        • 8.2.5.4.2.1. By Diagnosis
        • 8.2.5.4.2.2. By Treatment
        • 8.2.5.4.2.3. By Route of Administration
        • 8.2.5.4.2.4. By End User
      • 8.2.5.5. Australia Atherosclerosis Drugs Market Outlook
        • 8.2.5.5.1. Market Size & Forecast
        • 8.2.5.5.1.1. By Value
        • 8.2.5.5.2. Market Share & Forecast
        • 8.2.5.5.2.1. By Diagnosis
        • 8.2.5.5.2.2. By Treatment
        • 8.2.5.5.2.3. By Route of Administration
        • 8.2.5.5.2.4. By End User

9. South America Atherosclerosis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnosis
    • 9.2.2. By Treatment
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Brazil Atherosclerosis Drugs Market Outlook
        • 9.2.5.1.1. Market Size & Forecast
        • 9.2.5.1.1.1. By Value
        • 9.2.5.1.2. Market Share & Forecast
        • 9.2.5.1.2.1. By Diagnosis
        • 9.2.5.1.2.2. By Treatment
        • 9.2.5.1.2.3. By Route of Administration
        • 9.2.5.1.2.4. By End User
      • 9.2.5.2. Argentina Atherosclerosis Drugs Market Outlook
        • 9.2.5.2.1. Market Size & Forecast
        • 9.2.5.2.1.1. By Value
        • 9.2.5.2.2. Market Share & Forecast
        • 9.2.5.2.2.1. By Diagnosis
        • 9.2.5.2.2.2. By Treatment
        • 9.2.5.2.2.3. By Route of Administration
        • 9.2.5.2.2.4. By End User
      • 9.2.5.3. Colombia Atherosclerosis Drugs Market Outlook
        • 9.2.5.3.1. Market Size & Forecast
        • 9.2.5.3.1.1. By Value
        • 9.2.5.3.2. Market Share & Forecast
        • 9.2.5.3.2.1. By Diagnosis
        • 9.2.5.3.2.2. By Treatment
        • 9.2.5.3.2.3. By Route of Administration
        • 9.2.5.3.2.4. By End User

10. Middle East & Africa Atherosclerosis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnosis
    • 10.2.2. By Treatment
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
      • 10.2.5.1. South Africa Atherosclerosis Drugs Market Outlook
        • 10.2.5.1.1. Market Size & Forecast
        • 10.2.5.1.1.1. By Value
        • 10.2.5.1.2. Market Share & Forecast
        • 10.2.5.1.2.1. By Diagnosis
        • 10.2.5.1.2.2. By Treatment
        • 10.2.5.1.2.3. By Route of Administration
        • 10.2.5.1.2.4. By End User
      • 10.2.5.2. Saudi Arabia Atherosclerosis Drugs Market Outlook
        • 10.2.5.2.1. Market Size & Forecast
        • 10.2.5.2.1.1. By Value
        • 10.2.5.2.2. Market Share & Forecast
        • 10.2.5.2.2.1. By Diagnosis
        • 10.2.5.2.2.2. By Treatment
        • 10.2.5.2.2.3. By Route of Administration
        • 10.2.5.2.2.4. By End User
      • 10.2.5.3. UAE Atherosclerosis Drugs Market Outlook
        • 10.2.5.3.1. Market Size & Forecast
        • 10.2.5.3.1.1. By Value
        • 10.2.5.3.2. Market Share & Forecast
        • 10.2.5.3.2.1. By Diagnosis
        • 10.2.5.3.2.2. By Treatment
        • 10.2.5.3.2.3. By Route of Administration
        • 10.2.5.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Technology Launches

13. Competitive Landscape

  • 13.1. F. Hoffmann-La Roche Ltd.
    • 13.1.1. Business Overview
    • 13.1.2. Patient Offerings
    • 13.1.3. Recent Developments
    • 13.1.4. Key Personnel
    • 13.1.5. SWOT Analysis
  • 13.2. Mylan N.V.
  • 13.3. Teva Pharmaceutical Industries Ltd.
  • 13.4. Sanofi India
  • 13.5. Pfizer Inc.
  • 13.6. GlaxoSmithKline plc
  • 13.7. Novartis AG
  • 13.8. Merck & Co
  • 13.9. Allergan India Pvt Ltd.
  • 13.10. AstraZeneca

14. Strategic Recommendations

About us & Disclaimer